https://comparerx.org/news/retatrutide-beats-ozempic-head-to-head-trial-data CompareRx.org en 2026-10-29T04:15:23.037Z Lilly’s retatrutide beats Ozempic head-to-head — what 'triple-G' data means for cash buyers https://comparerx.org/news/lilly-retatrutide-beats-ozempic-head-to-head-trial CompareRx.org en 2026-10-28T12:15:28.929Z Lilly’s retatrutide beats Ozempic in head-to-head trial — what 'triple-G' data means for GLP-1 buyers https://comparerx.org/news/court-denies-novo-bid-block-lilly-ads CompareRx.org en 2026-10-27T20:15:24.826Z Judge denies Novo bid to block Eli Lilly GLP-1 ads — keeping the consumer marketing war active